Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?
MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.
All You Need to Know About Medifast (MED) Rating Upgrade to Buy
Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Medifast's New Compensation Plan Accelerate Coach Growth?
MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp decline in active earning coaches.
Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?
MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.
Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?
Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.
Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?
Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.
Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)
Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven.
Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves
MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.
Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
Medifast Q2 Earnings Call Highlights
Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter.
Medifast (MED) Reports Q2 Loss, Beats Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $0.04 per share a year ago.
